Drug intelligence / Profile preview

LXM.1

Development stage: Preclinical
Lead developer: Laxxon Medical
Modality: Small Molecules
Administration: Oral

Overview

LXM.1 is a preclinical-stage small molecule therapeutic being developed by Laxxon Medical for the treatment of epilepsy. The product is a 3D-printed oral formulation of the anticonvulsant levetiracetam, utilizing Laxxon's proprietary Screen Printing Innovative Technology (SPIT™). This 3D printing platform allows for the creation of complex, structured pharmaceutical dosage forms with precise, tailored release profiles, such as immediate or controlled release, which may improve the pharmacokinetic profile and patient compliance compared to traditional manufacturing methods. LXM.1 targets the synaptic vesicle protein 2A (SV2A) to modulate neurotransmitter release and provide anti-seizure activity.

Targets

SV2A (Synaptic vesicle glycoprotein 2A)

Beyond the preview

Go deeper on LXM.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LXM.1.

Explore the full profile